GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dermata Therapeutics Inc (NAS:DRMAW) » Definitions » Quick Ratio

Dermata Therapeutics (Dermata Therapeutics) Quick Ratio : 3.78 (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Dermata Therapeutics Quick Ratio?

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Dermata Therapeutics's quick ratio for the quarter that ended in Mar. 2024 was 3.78.

Dermata Therapeutics has a quick ratio of 3.78. It generally indicates good short-term financial strength.

The historical rank and industry rank for Dermata Therapeutics's Quick Ratio or its related term are showing as below:

DRMAW' s Quick Ratio Range Over the Past 10 Years
Min: 0.16   Med: 7.52   Max: 12.76
Current: 3.78

During the past 5 years, Dermata Therapeutics's highest Quick Ratio was 12.76. The lowest was 0.16. And the median was 7.52.

DRMAW's Quick Ratio is ranked better than
51.69% of 1540 companies
in the Biotechnology industry
Industry Median: 3.585 vs DRMAW: 3.78

Dermata Therapeutics Quick Ratio Historical Data

The historical data trend for Dermata Therapeutics's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dermata Therapeutics Quick Ratio Chart

Dermata Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Quick Ratio
1.20 0.16 7.66 7.52 4.91

Dermata Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Quick Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.70 12.76 7.99 4.91 3.78

Competitive Comparison of Dermata Therapeutics's Quick Ratio

For the Biotechnology subindustry, Dermata Therapeutics's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dermata Therapeutics's Quick Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Dermata Therapeutics's Quick Ratio distribution charts can be found below:

* The bar in red indicates where Dermata Therapeutics's Quick Ratio falls into.



Dermata Therapeutics Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

Dermata Therapeutics's Quick Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Quick Ratio (A: Dec. 2023 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(7.979-0)/1.624
=4.91

Dermata Therapeutics's Quick Ratio for the quarter that ended in Mar. 2024 is calculated as

Quick Ratio (Q: Mar. 2024 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(5.18-0)/1.372
=3.78

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Dermata Therapeutics  (NAS:DRMAW) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.


Dermata Therapeutics Quick Ratio Related Terms

Thank you for viewing the detailed overview of Dermata Therapeutics's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Dermata Therapeutics (Dermata Therapeutics) Business Description

Traded in Other Exchanges
Address
3525 Del Mar Heights Road, Suite No. 322, San Diego, CA, USA, 92130
Dermata Therapeutics Inc is a clinical-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, DMT310 and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to develop and formulate singular and combination products that are able to target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases.